Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 172 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease, Dementia
Interventions
Risperidone, Gabapentin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Menlo Park, California
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.

NCT02846740
Conditions
Suicide, Depression, Anxiety, Insomnia, Agitation
Interventions
Alpha-Stim®., Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale
Device · Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Agitation
Interventions
risperidone
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
4 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Alzheimer Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Sepsis, Respiratory Failure, Agitation
Interventions
Propofol, Dexmedetomidine, Fentanyl
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Dementia, Behavior Problems
Interventions
TREA (Treatment Routes for Exploring Agitation), Placebo Control Group
Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
Interventions
Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Conditions
Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia, Lewy Body Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Conditions
Migraine Headaches, Nausea, Restlessness
Interventions
Haloperidol, Metoclopramide 10mg, Diphenhydramine
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions
MP-101, Placebo
Drug
Lead sponsor
Mediti Pharma Inc.
Other
Eligibility
50 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
Conditions
Bipolar I Disorder
Interventions
Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more
Conditions
Delirium, Psychomotor Agitation
Interventions
Acupuncture
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Year to 6 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Alzheimer's Disease, Dementia
Interventions
high-intensity light therapy
Device
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
55 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Butner, North Carolina
Completed Not applicable Interventional Results available

Actigraphic Analysis of Treatment Response

NCT00723580
Conditions
Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
Interventions
risperidone
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Conditions
Agitation
Interventions
Ketamine-based protocol, Midazolam-based protocol
Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
9
States / cities
San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more
Conditions
Delirium, Agitation
Interventions
Risperidone, Trazodone, Placebo
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Rochester, New York
Conditions
Behavioral and Psychiatric Symptoms of Dementia, Dementia, Caregivers
Interventions
Intervention with Home-Based Caregivers
Other
Lead sponsor
University of Virginia
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions
IGC-AD1-Active, IGC-AD1-Placebo
Drug
Lead sponsor
IGC Pharma, LLC
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Conditions
Dementia
Interventions
Weighted Blanket
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Anxiety, Agitated Depression
Interventions
Music Listening, Listening to Audiobooks
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Los Angeles, California